Sage Therapeutics, Inc. (SAGE) Announces Quarterly Earnings Results, Beats Estimates By $0.01 EPS

Sage Therapeutics, Inc. (NASDAQ:SAGE) announced its earnings results on Thursday. The biopharmaceutical company reported ($1.97) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($1.98) by $0.01, Bloomberg Earnings reports. The firm’s revenue for the quarter was up .0% compared to the same quarter last year.

TRADEMARK VIOLATION NOTICE: “Sage Therapeutics, Inc. (SAGE) Announces Quarterly Earnings Results, Beats Estimates By $0.01 EPS” was first published by Community Financial News and is owned by of Community Financial News. If you are reading this news story on another website, it was stolen and reposted in violation of U.S. and international trademark and copyright law. The legal version of this news story can be read at https://www.com-unik.info/2017/11/03/sage-therapeutics-inc-sage-announces-quarterly-earnings-results-beats-estimates-by-0-01-eps.html.

Several research analysts recently weighed in on the company. Stifel Nicolaus reaffirmed a “buy” rating and set a $91.00 target price (down previously from $104.00) on shares of Sage Therapeutics in a research note on Wednesday, September 13th. J P Morgan Chase & Co reaffirmed a “buy” rating on shares of Sage Therapeutics in a research note on Thursday, August 31st. BMO Capital Markets reaffirmed a “buy” rating and set a $80.00 target price on shares of Sage Therapeutics in a research note on Friday, October 27th. Cowen and Company reaffirmed a “buy” rating and set a $100.00 target price on shares of Sage Therapeutics in a research note on Friday, August 4th. Finally, Goldman Sachs Group, Inc. (The) reaffirmed a “buy” rating and set a $87.00 target price on shares of Sage Therapeutics in a research note on Friday, October 6th. Four analysts have rated the stock with a hold rating, eleven have issued a buy rating and two have assigned a strong buy rating to the stock. The company has an average rating of “Buy” and a consensus target price of $86.71.

Sage Therapeutics Company Profile

SAGE Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in developing and commercializing medicines to treat central nervous system (CNS) disorders. The Company’s lead product candidate, SAGE-547 is an intravenous formulation of allopregnanolone, a neurosteroid that acts as a synaptic and extrasynaptic modulator of the Gamma-Amino Butyric Acid-A (GABAA) receptor.

Earnings History for Sage Therapeutics (NASDAQ:SAGE)

What are top analysts saying about Sage Therapeutics Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Sage Therapeutics Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit